OMCL Omnicell, Inc.
USHealthcareAs of 2026-07-10 16:00
Why OMCL matters now
Omnicell, Inc. (OMCL) is a US stock in Healthcare. The latest InvestLog snapshot shows $44.92 with -1.47% on the session and $2.04B in market capitalization; recent performance reads 1-month -10.89% and YTD -13.80%.
The latest financial table shown here is Q1 2026, with revenue of $309.9M, net income of $11.4M, and EPS of $0.25. Investors can compare that operating picture with valuation signals such as P/E 763.91 and FCF yield 6.3%.
The latest indexable market news headline is "Should You Continue to Hold OMCL Stock in Your Portfolio Now?" from Zacks Investment Research.
Additional event context on this page matters because analyst consensus is Buy with a median target of $55.00; recent insider activity includes Manley Corey J filing S-Sale. These signals are research inputs, not a recommendation.
Valuation
P/E (TTM)
763.91
PEG
—
P/B
1.41
P/S
1.45
EV/EBITDA
13.53
DCF Value
$26.67
FCF Yield
6.3%
Div Yield
0.0%
Margins & Returns
Gross Margin
43.5%
Operating Margin
2.8%
Net Margin
1.7%
ROE
1.6%
ROA
1.0%
ROIC
1.2%
Financials
| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $309.9M | $11.4M | $0.25 |
| Q4 2025 | $314.0M | $-2.0M | $-0.05 |
| FY 2025 | $1.18B | $2.1M | $0.04 |
| Q3 2025 | $310.6M | $5.5M | $0.12 |
Analyst Ratings
Consensus
Buy
Target (Consensus)
$57.20
Target (Median)
$55.00
Target Range
$49.00 - $70.00
Trading Activity
Insider Trades
Related Stocks
Latest News
Company Info
Sector
Healthcare
Industry
Medical - Healthcare Information Services
Country
US
Exchange
—
Beta
0.96
Omnicell, Inc., founded in 1992 and headquartered in Mountain View, California (initially operating as Omnicell Technologies, Inc. until its name change in 2001), delivers advanced medication management technologies and patient adherence solutions. The company serves healthcare systems and pharmacies both domestically within the United States and globally. Its extensive portfolio of offerings includes: Clinical Workflow Automation: Omnicell provides automated solutions designed to streamline clinician tasks in patient care environments. This encompasses the XT Series automated dispensing units for medications and supplies across nursing units, clinical areas, and surgical suites. They also offer interface software to ensure smooth integration between their products and a healthcare facility's existing information systems, alongside robotic systems for automated storage and retrieval of packaged medications. Central Pharmacy Optimization: For the central pharmacy, Omnicell offers sophisticated automation, including automated storage and retrieval platforms like the XR2 Automated Central Pharmacy System. This segment also features robotic systems and workflow management tools for IV compounding, comprehensive inventory management software, and systems for controlled substance oversight. Single-Dose Packaging for Adherence: The company develops automated technologies for filling and labeling patient-specific, single-dose medication blister packaging according to prescriptions. This includes both fully and semi-automated equipment for institutional pharmacies to ensure precise packaging, along with blister card packaging and supplies aimed at improving medication adherence, particularly in non-acute care settings. Digital Patient Engagement: Omnicell further provides EnlivenHealth Patient Engagement, a web-based platform offering various tools to interact with patients.